Cargando…

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

PURPOSE: Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of once-daily fenofibric acid or placebo on carotid intima-media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Michael, Rosenson, Robert S., Maki, Kevin C., Nicholls, Stephen J., Ballantyne, Christie M., Setze, Carolyn, Carlson, Dawn M., Stolzenbach, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407355/ https://www.ncbi.nlm.nih.gov/pubmed/22622962 http://dx.doi.org/10.1007/s10557-012-6395-z

Ejemplares similares

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides
por: Ballantyne, Christie M., et al.
Publicado: (2011)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus
por: Qasim, Muhammad, et al.
Publicado: (2022)

Carotid intima-media thickness, hypertension, and dyslipidemia in obese adolescents
por: Widjaja, Nur Aisiyah, et al.
Publicado: (2019)

Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
por: Krysiak, Robert, et al.
Publicado: (2010)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke
por: Khazaei, Mojtaba, et al.
Publicado: (2020)

Association of Subclinical Hypothyroidism with Dyslipidemia and Increased Carotid Intima-Media Thickness in Children
por: Unal, Edip, et al.
Publicado: (2017)

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
por: Han, Ji Soo, et al.
Publicado: (2018)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
por: Farnier, Michel
Publicado: (2008)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats
por: Zheng, Dongdan, et al.
Publicado: (2015)

Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia
por: Zhang, Wei-Li, et al.
Publicado: (2014)

Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms
por: Jain, N., et al.
Publicado: (2008)

Correlation study on the relationship between dyslipidemia and carotid intima-media thickness in patients with diabetes mellitus
por: Guo, Hong-jiang, et al.
Publicado: (2023)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes: A Meta-Analysis
por: Fang, Na, et al.
Publicado: (2015)

Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes
por: Najafipour, Mostafa, et al.
Publicado: (2018)

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
por: Chan, Dick C., et al.
Publicado: (2009)

Association of baseline Life’s Essential 8 score and trajectories with carotid intima-media thickness
por: Liu, Qian, et al.
Publicado: (2023)

Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia
por: Zheng, Dongdan, et al.
Publicado: (2017)

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy
por: Grandi, Anna M, et al.
Publicado: (2014)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial
por: Kimura, Genjiro, et al.
Publicado: (2016)

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate
por: Frazier-Wood, Alexis C., et al.
Publicado: (2014)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia
por: Lella, Meenakshi, et al.
Publicado: (2013)

Study of the intima-media thickening in carotid arteries of healthy elderly with high blood pressure and elderly with high blood pressure and dyslipidemia
por: de Freitas, Elizabete Viana, et al.
Publicado: (2008)

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)
por: Shaik, Aleesha, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Efficacy and Safety of Atorvastatin in South Asian Patients with Dyslipidemia: An Open Label Noncomparative Pilot Study
por: Patel, Jeetesh V, et al.
Publicado: (2005)

Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
por: Kim, Ji Min, et al.
Publicado: (2016)

Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function
por: Song, Xianbing, et al.
Publicado: (2014)

To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
por: Agrawal, Deepak, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iff9ec8p8q0ej6nbd5ep0hngfr